Previous 10 | Next 10 |
Today, we are posting a deep dive on CymaBay Therapeutics, one of the most volatile small-cap biotech names in the market. CymaBay's main drug candidate looks on its way to garnering FDA approval for primary biliary cholangitis. An analysis on CymaBay and what might be ahead for t...
NEWARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Leer...
The following slide deck was published by CymaBay Therapeutics, Inc. in conjunction with this event. For further details see: CymaBay Therapeutics (CBAY) Presents At AASLD 2020 Conference- Slideshow
Seladelpar demonstrated anti-cholestatic, anti-inflammatory, and anti-pruritic activity through 3 and 6 months Results highlight the potential for seladelpar to offer patients an efficacious and safe second line treatment option Global 52-week Phase 3 registrat...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
The FDA lifted all holds on all CymaBay liver disease studies back in July, since, shares have begun clawing back, +319% upside YTD. The company has presented positive top-line data from the ENHANCE study for Seladelpar, which shows high conversion potential in a complex chronic disea...
The following slide deck was published by CymaBay Therapeutics, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: CymaBay Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation
CymaBay Therapeutics, Inc. (CBAY) Q3 2020 Earnings Conference Call November 05, 2020 04:30 PM EST Company Participants Dan Menold - VP of Finance Sujal Shah - CEO Chuck McWherter - CSO Klara Dickinson - CRO Conference Call Participants Yasmeen Rahimi - Piper Sandler Steve Seedhouse - Raymond ...
Image source: The Motley Fool. CymaBay Therapeutics Inc. (NASDAQ: CBAY) Q3 2020 Earnings Call Nov 05, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: CymaBay Therapeutics Inc. (CBAY) Q3 2020 Earnings Call Transcript...
CymaBay announces trial design for RESPONSE , a global phase 3 registration stud y for seladelpar in primary biliary cholangitis (PBC) Results from the ENHANCE phase 3 study evaluating seladelpar for PBC to be featured in an oral ...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
2024-03-12 10:45:01 ET UiPath Inc (PATH) PATH is trading UP for the last 5 days, and it at trading at $24.64 with volume of 4,269,666 and a one day change of $0.54 (2.25%). UiPath Inc has a 52-week low of 12.38 and a 52-week high of $27.87. The business's 50-day moving average price...